Allen J. Duplantier

Allen J. Duplantier

Auto-generated profile, based on publicly available information

Allen J. Duplantier

Pfizer Global Research and Development, Groton Laboratories, Groton, CT 06340, USA

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Frontiers in Immunology
Verified
Journal Article
Open access
ADAllen J. Duplantier
Allen J. Duplantier
Monique L. van HoekMonique L. van Hoek
Monique L. van Hoek
Diabetic patients often have ulcers on their lower-limbs that are infected by multiple biofilm-forming genera of bacteria, and the elimination of the biofilm has proven highly successful in resolving such wounds in patients. To that end, antimicrobial peptides have shown potential as a new anti-biofilm approach. The single human cathelicidin peptide LL-37 has been shown to have antimicrobial and anti-biofilm activity against multiple Gram-positive and Gram-negative human pathogens, and have wound-healing effects on the host. The combination of the anti-biofilm effect and wound-healing properties of LL-37 may make it highly effective in resolving polymicrobially infected wounds when topically applied. Such a peptide or its derivatives could be a platform from which to develop new therapeutic strategies to treat biofilm-mediated infections of wounds. This review summarizes known mechanisms that regulate the endogenous levels of LL-37 and discusses the anti-biofilm, antibacterial, and immunological effects of deficient vs. excessive concentrations of LL-37 within the wound environment. Here, we review recent advances in understanding the therapeutic potential of this peptide and other clinically advanced peptides as a potential topical treatment for polymicrobial infected wounds.

1 January 1996 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ADAllen J. Duplantier
Allen J. Duplantier
MBMichael S. Biggers
Michael S. Biggers
RCRobert J. Chambers
Robert J. Chambers
JCJohn B. Cheng
John B. Cheng
KCKelvin Cooper
Kelvin Cooper
JWJohn W. Watson
John W. Watson

13 May 2009 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ADAllen J. Duplantier
Allen J. Duplantier
SBStacey L. Becker
Stacey L. Becker
MBMichael J. Bohanon
Michael J. Bohanon
KBKris A. Borzilleri
Kris A. Borzilleri
BCBoris A. Chrunyk
Boris A. Chrunyk
LZLei Zhang
Lei Zhang

7 March 2018 in mBio
Verified
Journal Article
Open access
PDF file
CCChih-Yuan Chiang
Chih-Yuan Chiang
IUIjeoma Uzoma
Ijeoma Uzoma
RMRichard T. Moore
Richard T. Moore
MGMerle Gilbert
Merle Gilbert
ADAllen J. Duplantier
Allen J. Duplantier
RPRekha Panchal
Rekha Panchal
Increasing incidences of multidrug resistance in pathogenic bacteria threaten our ability to treat and manage bacterial infection. The development and FDA approval of novel antibiotics have slowed over the past decade; therefore, the adoption and improvement of alternative therapeutic strategies are critical for addressing the threat posed by multidrug-resistant bacteria. Host-directed therapies utilize small-molecule drugs and proteins to alter the host response to pathogen infection. Here, we highlight strategies for modulating the host inflammatory response to enhance bacterial clearance, small-molecule potentiation of innate immunity, and targeting of host factors that are exploited by pathogen virulence factors. Application of state-of-the-art “omic” technologies, including proteomics, transcriptomics, and image-omics (image-based high-throughput phenotypic screening), combined with powerful bioinformatics tools will enable the modeling of key signaling pathways in the host-pathogen interplay and aid in the identification of host proteins for therapeutic targeting and the discovery of host-directed small molecules that will regulate bacterial infection. We conclude with an outlook on research needed to overcome the challenges associated with transitioning host-directed therapies into a clinical setting.

31 December 2009 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
COChristopher J. O’donnell
Christopher J. O’donnell
BRBruce N. Rogers
Bruce N. Rogers
BBBrian S. Bronk
Brian S. Bronk
DBDianne K. Bryce
Dianne K. Bryce
JCJotham W. Coe
Jotham W. Coe
LZLei Zhang
Lei Zhang

1 June 2011 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
ADAllen J. Duplantier
Allen J. Duplantier
MDMark A. Dombroski
Mark A. Dombroski
CSChakrapani Subramanyam
Chakrapani Subramanyam
ABAimee M. Beaulieu
Aimee M. Beaulieu
SCShang-Poa Chang
Shang-Poa Chang
KYKwansik Yoon
Kwansik Yoon